Nymox Pharmaceutical Co. (NASDAQ:NYMX) Director James George Robinson purchased 8,000 shares of the stock in a transaction on Monday, February 12th. The stock was bought at an average price of $3.27 per share, for a total transaction of $26,160.00. Following the completion of the transaction, the director now directly owns 3,107,850 shares of the company’s stock, valued at $10,162,669.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
James George Robinson also recently made the following trade(s):
- On Thursday, February 8th, James George Robinson purchased 10,000 shares of Nymox Pharmaceutical stock. The stock was bought at an average price of $3.37 per share, for a total transaction of $33,700.00.
- On Friday, February 2nd, James George Robinson purchased 5,000 shares of Nymox Pharmaceutical stock. The stock was bought at an average price of $3.47 per share, for a total transaction of $17,350.00.
- On Thursday, January 18th, James George Robinson purchased 3,000 shares of Nymox Pharmaceutical stock. The stock was bought at an average price of $3.14 per share, for a total transaction of $9,420.00.
Shares of Nymox Pharmaceutical Co. (NASDAQ NYMX) traded down $0.04 during trading hours on Tuesday, reaching $3.24. The company’s stock had a trading volume of 139,200 shares, compared to its average volume of 234,899. Nymox Pharmaceutical Co. has a 52-week low of $3.00 and a 52-week high of $5.10. The company has a current ratio of 1.44, a quick ratio of 1.42 and a debt-to-equity ratio of 61.64.
ILLEGAL ACTIVITY WARNING: “James George Robinson Purchases 8,000 Shares of Nymox Pharmaceutical Co. (NYMX) Stock” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/13/james-george-robinson-purchases-8000-shares-of-nymox-pharmaceutical-co-nymx-stock.html.
Nymox Pharmaceutical Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.